India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven ...

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025.

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist, ...

Rybelsus reduced the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo over an ...

Quack cardiac surgeries, World Health Day policies, Trump's healthcare decisions, anti-obesity drug coverage, and more health ...

Weight loss drugs like Ozempic gained popularity for managing obesity, diabetes, and related chronic conditions, a new study ...

Weight-loss jabs and those for diabetes may be linked to a lower risk of dementia, a study suggests. Semaglutide in ...

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new ...

Recent study shows oral semaglutide reduces cardiovascular risk in type 2 diabetes patients, enhancing diabetes and heart ...

Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to ...

They’re called “doctor’s orders” — not “doctor’s suggestions” — for a reason. “Real Housewives of New Jersey” star Jennifer ...